Find and Pitch Jounalists, Get Your Story Covered

Tags: smart home wi-fi shopping buying guides routers

	Profile	Recent Articles on Subject
1	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 3 days ago GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer - 3 months ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 4 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 8 months ago FDA Accepts Application, Grants Priority Review to Vorasidenib for IDH-Mutant Diffuse Glioma - 9 months ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	MHRA grants approval for bladder cancer drug erdafitinib - 18 days ago
3	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 27 days ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 29 days ago FDA Approves First Phosphate Absorption Inhibitor for CKD - about 1 year ago
4	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 2 months ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 4 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 8 months ago First-Line Nivolumab Plus Chemo Approved for Bladder Cancer - 9 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - 12 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago
6	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 5 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 11 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago
7	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 3 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - 10 months ago
8	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 5 months ago Regorafenib-Pembrolizumab Has 'Modest' Activity in HCC Post-Immunotherapy - 5 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 11 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis - about 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - about 1 year ago
9	Ryan Haumschild, PharmD, MS, MBA Pharmacy Times Director of Pharmacy. Editorial Board member. Atlanta, Georgia pharmacyhealthcareeditorial workadvisory	Alternative Treatments for eBC and mBC - 6 months ago Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment - about 1 year ago NCCN Guidelines on CDK4/6 Inhibitor Treatment Regimens - about 1 year ago Differentiating Between Adverse Event Profiles of Various CDK4/6 Inhibitors - about 1 year ago Progression-Free Survival and Overall Survival Associated With CDK4/6 Inhibitor Therapy - about 1 year ago
10	Randy Dotinga MedPage Today Indie scribbler, advocate. Board member, @ahcj. San Diego WritingAdvocacy	EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk - 11 months ago

Journalists covering CDK4/6 inhibitor therapy